http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
( Han Chul Lim ), ( Young Joon Hong ), ( Sang Wook Kim ), ( Young Mi Cho ), ( Ji Won Kim ), ( Jung A Choi ), ( Han Byul Kim ), ( Min Chul Kim ), ( Doo Sun Sim ), ( Ju Han Kim ), ( Youngkeun Ahn ), ( Myung Ho Jeo) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Impact of Ezetimibe/Simvastatin on neointimal response to Biolimus-eluting stent Implantation
<P>Background: The Korea Acute Myocardial Infarction Registry (KAMIR)-National Institutes of Health (NIH) registry has the aim of evaluating the clinical characteristics, management, and long-term outcomes of patients with acute myocardial infarction (AMI) in Korea. Methods and Results; Patients hospitalized for AMI in 20 tertiary university hospitals in Korea have been enrolled since November 2011. The study is expected to complete the scheduled enrollment of approximately 13,000 patients in October 2015, and follow-up duration is up to 5 years for each patient. As of October 2015, an interim analysis of 13,623 subjects was performed to understand the baseline clinical profiles of the study population. The mean age was 64.1 years; 73.5% were male; and 48.2% were diagnosed with ST-segment elevation AMI. Hypertension is a leading cause of AMI in Korea (51.2%), followed by smoking (38.5%) and diabetes mellitus (28.6%). Percutaneous coronary intervention was performed in 87.4% and its success rate was very high (99.4%). In-hospital, 1-year, and 2-year mortality rates were 3.9%, 4.3%, and 8.6%, respectively. The rates of major adverse cardiac events at 1 and 2 years were 9.6% and 18.8%, respectively. Conclusions: This analysis demonstrated the clinical characteristics of Korean AMI patients in comparison with those of other countries. It is necessary to develop guidelines for Asian populations to further improve their prognosis.</P>
Kim,,Jae-Min,Stewart,,Robert,Lee,,Yong-Seong,Lee,,Hee-Joon,Kim,,Min,Chul,Kim,,Ju-Wan,Kang,,Hee-Ju,Bae,,Kyung-Yeol,Kim,,Sung-Wan,Shin,,Il-Seon,Hong,,Young,Joon,Kim,,Ju,Han,Ahn,,Youngkeun,Jeong,,Myung,H American Medical Association 2018 JAMA Vol.320 No.4
<P>CONCLUSIONS AND RELEVANCE Among patients with depression following recent acute coronary syndrome, 24-week treatment with escitalopram compared with placebo resulted in a lower risk of major adverse cardiac events after a median of 8.1 years. Further research is needed to assess the generalizability of these findings.</P>
Kim,,Hyun,Kuk,Hong,,Young,Joon,Jeong,,Myung,Ho,Kim,,Weon,Kim,,Sung,Soo,Ko,,Jum,Suk,Lee,,Min,Goo,Sim,,Doo,Sun,Park,,Keun,Ho,Yoon,,Nam,Sik,Yoon,,Hyun,Ju,Kim,,Kye,Hun,Park,,Hyung,Wook,Kim,,Ju,Han,Ahn,,Yo The Korean Association of Internal Medicine 2011 The Korean Journal of Internal Medicine Vol.26 No.1
<P><B>Background/Aims</B></P><P>Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration. The aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes after stent implantation in patients with coronary artery disease.</P><P><B>Methods</B></P><P>We performed a prospective trial with male subjects to compare the safety and effects of carvedilol-loaded BiodivYsio® stents implanted into 20 patients with those of bare-metal BiodivYsio® stents implanted into 21 patients for de novo coronary lesions. The primary end point was the degree of neointimal hyperplasia, which was measured by intravascular ultrasound (IVUS) 6 months after the procedure; the secondary end point was major adverse cardiac events (MACE) at 2 years after implantation. All carvedilol and control stents were deployed successfully.</P><P><B>Results</B></P><P>A 2-year follow-up was completed for 19 patients (95%) in the carvedilol stent group and 20 patients (95%) in the control stent group. IVUS showed a trend toward a larger luminal area (6.86 ± 2.59 vs. 5.47 ± 1.52 mm<SUP>2</SUP>, <I>p</I> = 0.267), smaller neointimal area (1.34 ± 0.70 vs. 2.40 ± 1.73 mm<SUP>2</SUP>, <I>p</I> = 0.18), and reduced net decrease in luminal area (-0.78 ± 0.97 vs. -1.89 ± 1.78 mm<SUP>2</SUP>, <I>p</I> = 0.106) in the carvedilol stent group compared with the control stent group, respectively. There were no significant differences in the incidence of MACE (10.5 vs. 30.0%, respectively, <I>p</I> = 0.132) between the groups at 2 years after stent implantation. Stent thrombosis did not occur in either group after 2 years.</P><P><B>Conclusions</B></P><P>The carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of cardiac death, myocardial infarction, or stent thrombosis at 2-year follow-up.</P>
Hong,,Young,Joon,Jeong,,Myung,Ho,Kim,,Dong,Han,Lee,,Ki,Hong,Lee,,Min,Goo,Park,,Keun,Ho,Sim,,Doo,Sun,Lee,,Sang,Hyun,Kim,,Han,Gyun,Yoon,,Nam,Sik,Yoon,,Hyun,Ju,Kim,,Kye,Hun,Park,,Hyung,Wook,Kim,,Ju,Han,A Elsevier 2012 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY - Vol.59 No.13